

Sanjay J Mathew

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3695880/publications.pdf>

Version: 2024-02-01

167
papers

11,677
citations

36303

51
h-index

30087

103
g-index

172
all docs

172
docs citations

172
times ranked

9550
citing authors

#	ARTICLE	IF	CITATIONS
1	Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial. <i>American Journal of Psychiatry</i> , 2013, 170, 1134-1142.	7.2	965
2	Rapid and Longer-Term Antidepressant Effects of Repeated Ketamine Infusions in Treatment-Resistant Major Depression. <i>Biological Psychiatry</i> , 2013, 74, 250-256.	1.3	632
3	Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression. <i>Biological Psychiatry</i> , 2010, 67, 139-145.	1.3	589
4	Effects of Intravenous Ketamine on Explicit and Implicit Measures of Suicidality in Treatment-Resistant Depression. <i>Biological Psychiatry</i> , 2009, 66, 522-526.	1.3	525
5	The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. <i>American Journal of Psychiatry</i> , 2018, 175, 150-158.	7.2	476
6	A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. <i>JAMA Psychiatry</i> , 2017, 74, 399.	11.0	433
7	Ketamine for Depression: <i>Where Do We Go from Here?</i> . <i>Biological Psychiatry</i> , 2012, 72, 537-547.	1.3	353
8	Neurobiological mechanisms in major depressive disorder. <i>Cmaj</i> , 2009, 180, 305-313.	2.0	348
9	Targeting glutamate signalling in depression: progress and prospects. <i>Nature Reviews Drug Discovery</i> , 2017, 16, 472-486.	46.4	345
10	EFFECTS OF KETAMINE ON EXPLICIT AND IMPLICIT SUICIDAL COGNITION: A RANDOMIZED CONTROLLED TRIAL IN TREATMENT-RESISTANT DEPRESSION. <i>Depression and Anxiety</i> , 2014, 31, 335-343.	4.1	275
11	Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. <i>International Journal of Neuropsychopharmacology</i> , 2010, 13, 71-82.	2.1	239
12	Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). <i>Molecular Psychiatry</i> , 2020, 25, 1592-1603.	7.9	235
13	Amino Acid Neurotransmitters Assessed by Proton Magnetic Resonance Spectroscopy: Relationship to Treatment Resistance in Major Depressive Disorder. <i>Biological Psychiatry</i> , 2009, 65, 792-800.	1.3	227
14	Ketamine for Treatment-Resistant Unipolar Depression. <i>CNS Drugs</i> , 2012, 26, 189-204.	5.9	203
15	Novel Drugs and Therapeutic Targets for Severe Mood Disorders. <i>Neuropsychopharmacology</i> , 2008, 33, 2080-2092.	5.4	199
16	Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 331-336.	2.1	195
17	Ketamine Safety and Tolerability in Clinical Trials for Treatment-Resistant Depression. <i>Journal of Clinical Psychiatry</i> , 2015, 76, 247-252.	2.2	179
18	Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists. <i>CNS Drugs</i> , 2010, 24, 669-693.	5.9	156

#	ARTICLE	IF	CITATIONS
19	Neurobiological Mechanisms of Social Anxiety Disorder. American Journal of Psychiatry, 2001, 158, 1558-1567.	7.2	148
20	Molecular targets in the treatment of anxiety. Biological Psychiatry, 2002, 52, 1008-1030.	1.3	147
21	Recent advances in the neurobiology of anxiety disorders: Implications for novel therapeutics. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2008, 148C, 89-98.	1.6	139
22	Increased ventricular lactate in chronic fatigue syndrome. III. Relationships to cortical glutathione and clinical symptoms implicate oxidative stress in disorder pathophysiology. NMR in Biomedicine, 2012, 25, 1073-1087.	2.8	134
23	Anxiety disorders: a comprehensive review of pharmacotherapies. Mount Sinai Journal of Medicine, 2008, 75, 248-262.	1.9	130
24	Endogenous opioid system dysregulation in depression: implications for new therapeutic approaches. Molecular Psychiatry, 2019, 24, 576-587.	7.9	130
25	A randomized proof-of-mechanism trial applying the "fast-fail" approach to evaluating μ -opioid antagonism as a treatment for anhedonia. Nature Medicine, 2020, 26, 760-768.	30.7	129
26	Open-Label Trial of Riluzole in Generalized Anxiety Disorder. American Journal of Psychiatry, 2005, 162, 2379-2381.	7.2	119
27	Neurocognitive Effects of Ketamine and Association with Antidepressant Response in Individuals with Treatment-Resistant Depression: A Randomized Controlled Trial. Neuropsychopharmacology, 2015, 40, 1084-1090.	5.4	117
28	Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study. Neuropsychopharmacology, 2017, 42, 844-853.	5.4	99
29	Therapeutic infusions of ketamine: Do the psychoactive effects matter?. Drug and Alcohol Dependence, 2014, 136, 153-157.	3.2	98
30	The Nucleus Accumbens and Ketamine Treatment in Major Depressive Disorder. Neuropsychopharmacology, 2017, 42, 1739-1746.	5.4	94
31	A Single Ketamine Infusion Combined With Mindfulness-Based Behavioral Modification to Treat Cocaine Dependence: A Randomized Clinical Trial. American Journal of Psychiatry, 2019, 176, 923-930.	7.2	94
32	A magnetic resonance spectroscopic imaging study of adult nonhuman primates exposed to early-life stressors. Biological Psychiatry, 2003, 54, 727-735.	1.3	93
33	Regulation of neural responses to emotion perception by ketamine in individuals with treatment-resistant major depressive disorder. Translational Psychiatry, 2015, 5, e509-e509.	4.8	93
34	Neurobiology of anxiety disorders and implications for treatment. Mount Sinai Journal of Medicine, 2006, 73, 941-9.	1.9	93
35	Twenty-four-hour cortisol secretion patterns in prepubertal children with anxiety or depressive disorders. Biological Psychiatry, 2004, 56, 198-204.	1.3	83
36	The Emerging Use of Ketamine for Anesthesia and Sedation in Traumatic Brain Injuries. CNS Neuroscience and Therapeutics, 2013, 19, 390-395.	3.9	80

#	ARTICLE	IF	CITATIONS
37	Early-life stress, corpus callosum development, hippocampal volumetrics, and anxious behavior in male nonhuman primates. <i>Psychiatry Research - Neuroimaging</i> , 2011, 192, 37-44.	1.8	78
38	Dorsolateral Prefrontal Cortical Pathology in Generalized Anxiety Disorder: A Proton Magnetic Resonance Spectroscopic Imaging Study. <i>American Journal of Psychiatry</i> , 2004, 161, 1119-1121.	7.2	74
39	Corticotropin-Releasing Factor Receptor 1 Antagonism Is Ineffective for Women With Posttraumatic Stress Disorder. <i>Biological Psychiatry</i> , 2017, 82, 866-874.	1.3	74
40	Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response. <i>Psychopharmacology</i> , 2014, 231, 481-488.	3.1	73
41	Prefrontal Connectivity and Glutamate Transmission: Relevance to Depression Pathophysiology and Ketamine Treatment. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2017, 2, 566-574.	1.5	72
42	The promise of ketamine for treatment-resistant depression: current evidence and future directions. <i>Annals of the New York Academy of Sciences</i> , 2015, 1345, 47-58.	3.8	70
43	Ventricular cerebrospinal fluid lactate is increased in chronic fatigue syndrome compared with generalized anxiety disorder: an <i>in vivo</i> 3.0 T ¹ H MRS imaging study. <i>NMR in Biomedicine</i> , 2009, 22, 251-258.	2.8	68
44	Increased ventricular lactate in chronic fatigue syndrome measured by ¹ H MRS imaging at 3.0 T. II: comparison with major depressive disorder. <i>NMR in Biomedicine</i> , 2010, 23, 643-650.	2.8	68
45	Hippocampal volume and the rapid antidepressant effect of ketamine. <i>Journal of Psychopharmacology</i> , 2015, 29, 591-595.	4.0	67
46	The role of early life stress in development of the anterior limb of the internal capsule in nonhuman primates. <i>Neuroscience Letters</i> , 2010, 480, 93-96.	2.1	65
47	The Neurobiological Mechanisms of Generalized Anxiety Disorder and Chronic Stress. <i>Chronic Stress</i> , 2017, 1, 247054701770399.	3.4	62
48	Hippocampal N-Acetylaspartate Concentration and Response to Riluzole in Generalized Anxiety Disorder. <i>Biological Psychiatry</i> , 2008, 63, 891-898.	1.3	61
49	A pilot study of hippocampal volume and N-acetylaspartate (NAA) as response biomarkers in riluzole-treated patients with GAD. <i>European Neuropsychopharmacology</i> , 2013, 23, 276-284.	0.7	58
50	Deep Brain Stimulation for Depression Informed by Intracranial Recordings. <i>Biological Psychiatry</i> , 2022, 92, 246-251.	1.3	58
51	Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: a double-blind, randomized, placebo-controlled trial. <i>Bipolar Disorders</i> , 2012, 14, 64-70.	1.9	57
52	Differentiating Depressed Adolescent 24-h Cortisol Secretion in Light of Their Adult Clinical Outcome. <i>Neuropsychopharmacology</i> , 2003, 28, 1336-1343.	5.4	54
53	Prefrontal cortical GABA abnormalities are associated with reduced hippocampal volume in major depressive disorder. <i>European Neuropsychopharmacology</i> , 2015, 25, 1082-1090.	0.7	52
54	The first implementation of the NIMH FAST-FAIL approach to psychiatric drug development. <i>Nature Reviews Drug Discovery</i> , 2019, 18, 82-84.	46.4	52

#	ARTICLE	IF	CITATIONS
55	Publication Bias and the Efficacy of Antidepressants. <i>American Journal of Psychiatry</i> , 2009, 166, 140-145.	7.2	50
56	Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS). <i>Neuropsychopharmacology</i> , 2020, 45, 1656-1663.	5.4	50
57	Synchronized Maternal-Infant Elevations of Primate CSF CRF Concentrations in Response to Variable Foraging Demand. <i>CNS Spectrums</i> , 2005, 10, 530-536.	1.2	48
58	Neurobiology of early life stress: Nonhuman primate models. <i>Seminars in Clinical Neuropsychiatry</i> , 2002, 7, 96-103.	1.9	48
59	In vivo 1H MRS study of potential associations between glutathione, oxidative stress and anhedonia in major depressive disorder. <i>Neuroscience Letters</i> , 2014, 569, 74-79.	2.1	45
60	A selective neurokinin-1 receptor antagonist in chronic PTSD: A randomized, double-blind, placebo-controlled, proof-of-concept trial. <i>European Neuropsychopharmacology</i> , 2011, 21, 221-229.	0.7	44
61	Cerebrospinal Fluid Concentrations of Biogenic Amines and Corticotropin-releasing Factor in Adolescent Non-human Primates as a Function of the Timing of Adverse Early Rearing. <i>Stress</i> , 2002, 5, 185-193.	1.8	43
62	Glutamate modulators as novel interventions for mood disorders. <i>Revista Brasileira De Psiquiatria</i> , 2005, 27, 243-248.	1.7	42
63	Treatment-resistant depression: recent developments and future directions. <i>Depression and Anxiety</i> , 2008, 25, 989-992.	4.1	42
64	Decreased choline and creatine concentrations in centrum semiovale in patients with generalized anxiety disorder: Relationship to IQ and early trauma. <i>Psychiatry Research - Neuroimaging</i> , 2006, 147, 27-39.	1.8	41
65	Glutamate and anxiety disorders. <i>Current Psychiatry Reports</i> , 2007, 9, 278-283.	4.5	41
66	Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trial. <i>Trials</i> , 2014, 15, 240.	1.6	41
67	Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression. <i>Journal of Psychiatric Research</i> , 2019, 110, 166-171.	3.1	41
68	Glutamate Hypothalamic-Pituitary-Adrenal Axis Interactions: Implications for Mood and Anxiety Disorders. <i>CNS Spectrums</i> , 2001, 6, 555-564.	1.2	39
69	Does Ketamine Have Anti-Suicidal Properties? Current Status and Future Directions. <i>CNS Drugs</i> , 2015, 29, 181-188.	5.9	39
70	Early life stress and macaque amygdala hypertrophy: preliminary evidence for a role for the serotonin transporter gene. <i>Frontiers in Behavioral Neuroscience</i> , 2014, 8, 342.	2.0	38
71	Maternal-Infant Response to Variable Foraging Demand in Nonhuman Primates: Effects of Timing of Stressor on Cerebrospinal Fluid Corticotropin-Releasing Factor and Circulating Glucocorticoid Concentrations. <i>Annals of the New York Academy of Sciences</i> , 2006, 1071, 525-533.	3.8	37
72	Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression. <i>Depression and Anxiety</i> , 2019, 36, 235-243.	4.1	37

#	ARTICLE	IF	CITATIONS
73	A Case of Sustained Remission Following an Acute Course of Ketamine in Treatment-Resistant Depression. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 414-415.	2.2	37
74	Tryptophan Depletion and Emotional Processing in Healthy Volunteers at High Risk for Depression. <i>Biological Psychiatry</i> , 2011, 69, 804-807.	1.3	36
75	A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder. <i>Neuropsychopharmacology</i> , 2017, 42, 2567-2574.	5.4	36
76	DNA methylation levels are associated with CRF1 receptor antagonist treatment outcome in women with post-traumatic stress disorder. <i>Clinical Epigenetics</i> , 2018, 10, 136.	4.1	36
77	Cognition, functional capacity, and self-reported disability in women with posttraumatic stress disorder: Examining the convergence of performance-based measures and self-reports. <i>Journal of Psychiatric Research</i> , 2014, 57, 51-57.	3.1	35
78	Impact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant. <i>Neuropsychopharmacology</i> , 2019, 44, 1233-1238.	5.4	35
79	ELEctroconvulsive therapy (ECT) vs. Ketamine in patients with Treatment-resistant Depression: The ELEKT-D study protocol. <i>Contemporary Clinical Trials</i> , 2019, 77, 19-26.	1.8	34
80	Serum and plasma brain-derived neurotrophic factor and response in a randomized controlled trial of riluzole for treatment resistant depression. <i>Journal of Affective Disorders</i> , 2018, 241, 514-518.	4.1	33
81	Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled Trial. <i>American Journal of Psychiatry</i> , 2021, 178, 437-446.	7.2	33
82	Balancing the Promise and Risks of Ketamine Treatment for Mood Disorders. <i>Neuropsychopharmacology</i> , 2017, 42, 1179-1181.	5.4	30
83	Habenula Connectivity and Intravenous Ketamine in Treatment-Resistant Depression. <i>International Journal of Neuropsychopharmacology</i> , 2021, 24, 383-391.	2.1	28
84	Combined effects of genotype and childhood adversity shape variability of DNA methylation across age. <i>Translational Psychiatry</i> , 2021, 11, 88.	4.8	27
85	Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression. <i>Translational Psychiatry</i> , 2018, 8, 280.	4.8	26
86	Trajectories of self-reported sleep disturbance across inpatient psychiatric treatment predict clinical outcome in comorbid major depressive disorder and generalized anxiety disorder. <i>Journal of Affective Disorders</i> , 2019, 251, 248-255.	4.1	25
87	Body Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2020, 40, 287-292.	1.4	25
88	Effects of PRX-00023, a Novel, Selective Serotonin 1A Receptor Agonist on Measures of Anxiety and Depression in Generalized Anxiety Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 235-239.	1.4	21
89	The Relationship between Intelligence and Anxiety: An Association with Subcortical White Matter Metabolism. <i>Frontiers in Evolutionary Neuroscience</i> , 2011, 3, 8.	3.7	21
90	Reduced hippocampal N-acetyl-aspartate (NAA) as a biomarker for overweight. <i>NeuroImage: Clinical</i> , 2014, 4, 326-335.	2.7	21

#	ARTICLE	IF	CITATIONS
91	Psychopharmacological Agents and Suicide Risk Reduction: Ketamine and Other Approaches. <i>Current Psychiatry Reports</i> , 2015, 17, 81.	4.5	21
92	Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression. <i>Journal of Affective Disorders</i> , 2020, 260, 131-139.	4.1	21
93	Ketamine for depression clinical issues. <i>Advances in Pharmacology</i> , 2020, 89, 131-162.	2.0	20
94	Early-life stress and neurometabolites of the hippocampus. <i>Brain Research</i> , 2010, 1358, 191-199.	2.2	19
95	Psychophysiological treatment outcomes: Corticotropin-releasing factor type 1 receptor antagonist increases inhibition of fear-potentiated startle in PTSD patients. <i>Psychophysiology</i> , 2020, 57, e13356.	2.4	19
96	Etiology and neurobiology of social anxiety disorder. <i>Journal of Clinical Psychiatry</i> , 2006, 67 Suppl 12, 9-13.	2.2	19
97	A pilot study of the effects of chronic paroxetine administration on hippocampal N-acetylaspartate in generalized anxiety disorder. <i>Journal of Psychopharmacology</i> , 2010, 24, 1175-1181.	4.0	18
98	Elevated cerebrospinal fluid 5-hydroxyindoleacetic acid in macaques following early life stress and inverse association with hippocampal volume: preliminary implications for serotonin-related function in mood and anxiety disorders. <i>Frontiers in Behavioral Neuroscience</i> , 2014, 8, 440.	2.0	18
99	Effects of LY354740, a Novel Glutamatergic Metabotropic Agonist, on Nonhuman Primate Hypothalamic-Pituitary-Adrenal Axis and Noradrenergic Function. <i>CNS Spectrums</i> , 2001, 6, 607-617.	1.2	17
100	The Impact of Childhood Maltreatment on Intravenous Ketamine Outcomes for Adult Patients with Treatment-Resistant Depression. <i>Pharmaceuticals</i> , 2019, 12, 133.	3.8	17
101	The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: Results from a randomized double-blind study. <i>European Neuropsychopharmacology</i> , 2021, 49, 122-132.	0.7	17
102	Attitudes Toward Neurosurgical Procedures for Parkinson's Disease and Obsessive-Compulsive Disorder. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 1999, 11, 259-267.	1.8	16
103	Riluzole effect on occipital cortex: A structural and spectroscopy pilot study. <i>Neuroscience Letters</i> , 2012, 530, 103-107.	2.1	16
104	Longer-term open-label study of adjunctive riluzole in treatment-resistant depression. <i>Journal of Affective Disorders</i> , 2019, 258, 102-108.	4.1	16
105	Vortioxetine Versus Placebo for Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2021, 82, .	2.2	16
106	Impact of childhood emotional abuse on neocortical neurometabolites and complex emotional processing in patients with generalized anxiety disorder. <i>Journal of Affective Disorders</i> , 2016, 190, 414-423.	4.1	15
107	Novel investigational therapeutics for generalized anxiety disorder (GAD). <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 1003-1012.	4.1	15
108	Objective measurement of sleep, heart rate, heart rate variability, and physical activity in suicidality: A systematic review. <i>Journal of Affective Disorders</i> , 2020, 273, 318-327.	4.1	15

#	ARTICLE	IF	CITATIONS
109	A randomized cross-over trial to define neurophysiological correlates of AV-101 N-methyl-d-aspartate receptor blockade in healthy veterans. <i>Neuropsychopharmacology</i> , 2021, 46, 820-827.	5.4	15
110	Neuroendocrine predictors of response to intravenous clomipramine therapy for refractory obsessive-compulsive disorder. <i>Depression and Anxiety</i> , 2001, 14, 199-208.	4.1	13
111	Neurostimulatory therapeutics in management of treatment-resistant depression with focus on deep brain stimulation. <i>Mount Sinai Journal of Medicine</i> , 2008, 75, 263-275.	1.9	13
112	Placebo Effects Across Self-Report, Clinician Rating, and Objective Performance Tasks Among Women With Post-Traumatic Stress Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 200-206.	1.4	13
113	A Proof-of-Mechanism Study to Test Effects of the NMDA Receptor Antagonist Lanicemine on Behavioral Sensitization in Individuals With Symptoms of PTSD. <i>Frontiers in Psychiatry</i> , 2019, 10, 846.	2.6	13
114	Impulsivity and Suicidal Behavior. <i>Current Topics in Behavioral Neurosciences</i> , 2020, 47, 179-195.	1.7	13
115	An Update on Community Ketamine Practices. <i>American Journal of Psychiatry</i> , 2022, 179, 393-394.	7.2	13
116	Operationalizing NIMH Research Domain Criteria (RDoC) in naturalistic clinical settings. <i>Bulletin of the Menninger Clinic</i> , 2016, 80, 187-212.	0.6	12
117	Identification of an optimal dose of intravenous ketamine for late-life treatment-resistant depression: a Bayesian adaptive randomization trial. <i>Neuropsychopharmacology</i> , 2022, 47, 1088-1095.	5.4	12
118	Glycine Transporter-I Inhibitors: A New Class of Antidepressant?. <i>Biological Psychiatry</i> , 2013, 74, 710-711.	1.3	9
119	Assessment of the Efficacy and Safety of BMS-820836 in Patients With Treatment-Resistant Major Depression. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 454-459.	1.4	9
120	Interactions of immediate and long-term action regulation in the course and complications of bipolar disorder. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2019, 374, 20180132.	4.0	9
121	Bayesian adaptive randomization trial of intravenous ketamine for veterans with late-life, treatment-resistant depression. <i>Contemporary Clinical Trials Communications</i> , 2019, 16, 100432.	1.1	8
122	Distinct trajectories of antidepressant response to intravenous ketamine. <i>Journal of Affective Disorders</i> , 2021, 286, 320-329.	4.1	8
123	Ketamine for treatment of mood disorders and suicidality: A narrative review of recent progress. , 2021, 33, e10-e20.		8
124	Diffusion tensor imaging in studying white matter complexity: A gap junction hypothesis. <i>Neuroscience Letters</i> , 2010, 475, 161-164.	2.1	7
125	A Novel Anxiety and Affective Spectrum Disorder of Mind and Body—The ALPIM (Anxiety-Laxity-Pain-Immune-Mood) Syndrome: A Preliminary Report. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2015, 27, 93-103.	1.8	7
126	Patterns of anterior versus posterior white matter fractional anisotropy concordance in adult nonhuman primates: Effects of early life stress. <i>Journal of Affective Disorders</i> , 2016, 192, 167-175.	4.1	7

#	ARTICLE	IF	CITATIONS
127	Neurometabolic Abnormalities in Treatment-Resistant Depression. American Journal of Psychiatry, 2017, 174, 3-5.	7.2	7
128	Neurobiology of the dorsolateral prefrontal cortex in GAD: Aberrant neurometabolic correlation to hippocampus and relationship to anxiety sensitivity and IQ. Journal of Affective Disorders, 2018, 229, 1-13.	4.1	7
129	Short-term tolerability of a nonazapirone selective serotonin 1A agonist in adults with generalized anxiety disorder: A 28-day, open-label study. Clinical Therapeutics, 2008, 30, 1658-1666.	2.5	6
130	Early Life Stress Associated With Increased Striatal N-Acetyl-Aspartate: Cerebrospinal Fluid Corticotropin-Releasing Factor Concentrations, Hippocampal Volume, Body Mass, and Behavioral Correlates. Chronic Stress, 2018, 2, 247054701876845.	3.4	6
131	Does the Opioid System Block or Enhance the Antidepressant Effects of Ketamine?. Chronic Stress, 2019, 3, 247054701985207.	3.4	6
132	Q-15 checks and 1:1 observations: Exacerbating a problem we are trying to solve?. Journal of Affective Disorders, 2020, 263, 552-554.	4.1	6
133	Neurophysiological and clinical effects of the NMDA receptor antagonist lanicemine (BHVâ€5500) in PTSD: A randomized, double-blind, placebo-controlled trial. Depression and Anxiety, 2021, 38, 1108-1119.	4.1	6
134	Glutamate Modulation in Mood and Anxiety Disorders: Toward a Rational Pharmacology?. CNS Spectrums, 2005, 10, 806-807.	1.2	5
135	Enhanced Olfactory Cortex Connectivity in a Patient With PTSD With Olfactory Hallucinations. Journal of Neuropsychiatry and Clinical Neurosciences, 2015, 27, e170-e171.	1.8	5
136	Metabolic syndrome and neurometabolic asymmetry of hippocampus in adult bonnet monkeys. Physiology and Behavior, 2011, 103, 535-539.	2.1	4
137	Temporal Stability of Cognitive Functioning and Functional Capacity in Women with Posttraumatic Stress Disorder. Archives of Clinical Neuropsychology, 2019, 34, 539-547.	0.5	4
138	The Implications of Neurocognitive Deficits in Posttraumatic Stress Disorder. Psychiatric Annals, 2011, 41, 408-412.	0.1	4
139	Anxiety and depression: leading edge of therapy. Mount Sinai Journal of Medicine, 2008, 75, 171-173.	1.9	3
140	Psychotherapy for Mixed Depression and Mixed Mania. Psychiatric Clinics of North America, 2020, 43, 199-211.	1.3	3
141	Ketamine Plus Motivational Enhancement Therapy: Leveraging a Rapid Effect to Promote Enduring Change. American Journal of Psychiatry, 2020, 177, 107-109.	7.2	3
142	Wearable technology: A promising opportunity to improve inpatient psychiatry safety and outcomes. Journal of Psychiatric Research, 2021, 135, 104-106.	3.1	3
143	Does mismatch negativity have utility for NMDA receptor drug development in depression?. Revista Brasileira De Psiquiatria, 2022, 44, 61-73.	1.7	3
144	Treatment Strategies for Obsessive-Compulsive Disorder. Psychiatric Annals, 2000, 30, 699-708.	0.1	3

#	ARTICLE	IF	CITATIONS
145	A Case of Intranasal Ketamine Misuse: Considerations for Clinical Practice. <i>Journal of Psychiatric Practice</i> , 2021, 27, 492-495.	0.7	3
146	Pharmacotherapy for Generalized Anxiety Disorder. , 2008, , .		2
147	Heightened early-attentional stimulus orienting and impulsive action in men with antisocial personality disorder. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2017, 267, 697-707.	3.2	2
148	Computational Approaches for Studying Mechanisms of Psychiatric Disorders. , 2016, , .		2
149	Is Testosterone an Effective Hormonal Therapy for Women With Antidepressant-Resistant Major Depression?. <i>American Journal of Psychiatry</i> , 2020, 177, 891-894.	7.2	2
150	Drs. Mathew and Charney Reply. <i>American Journal of Psychiatry</i> , 2009, 166, 934-934.	7.2	1
151	Overcoming Antidepressant Treatment Resistance: Focus on Glutamate. <i>Modern Problems of Pharmacopsychiatry</i> , 2010, , 89-100.	2.5	1
152	Ketamine Treatment for Major Depression. <i>Psychopharm Review: Timely Reports in Psychopharmacology and Device-based Therapies</i> , 2011, 46, 89-96.	0.1	1
153	Ketamine in treatment-resistant depression. , 0, , 345-357.		1
154	549. DNA Methylation Biomarkers and Treatment Effects of a Corticotropin Releasing Hormone Type 1 Receptor Antagonist in a Biologically-Defined Subset of PTSD-Patients. <i>Biological Psychiatry</i> , 2017, 81, S222.	1.3	1
155	F172. Clinical Evaluation of Abuse Potential of ALKS 5461. <i>Biological Psychiatry</i> , 2018, 83, S305.	1.3	1
156	A Novel Approach to Link Genetics and Human MRI Identifies AKAP7-Dependent Subicular/Prefrontal Functional Connectivity as Altered in Suicidality. <i>Chronic Stress</i> , 2022, 6, 247054702210837.	3.4	1
157	A comparison of the safety, feasibility, and tolerability of ECT and ketamine for treatment-resistant depression. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 745-759.	2.4	1
158	Nighttime Sleep Quality and Daytime Sleepiness Predicts Suicide Risk in Adults Admitted to an Inpatient Psychiatric Hospital. <i>Behavioral Sleep Medicine</i> , 2022, , 1-13.	2.1	1
159	Molecular imaging of other anxiety disorders. , 0, , 295-307.		0
160	S.7.3 - KETAMINE AND NMDA RECEPTOR MODULATION FOR TREATMENT-RESISTANT MOOD DISORDERS. <i>Behavioural Pharmacology</i> , 2013, 24, e8-e9.	1.7	0
161	525. The Temporal Stability of Cognitive Functioning and Functional Capacity in Women with PTSD. <i>Biological Psychiatry</i> , 2017, 81, S213.	1.3	0
162	130. Childhood Trauma and Impulsivity in Adult Mood and Anxiety Disorders: Evidence of Behavioral Sensitization?. <i>Biological Psychiatry</i> , 2017, 81, S54-S55.	1.3	0

#	ARTICLE	IF	CITATIONS
163	F179. Epigenetic Biomarkers in Women With Posttraumatic Stress Disorder After CRF1 Receptor Antagonist Treatment. <i>Biological Psychiatry</i> , 2018, 83, S308.	1.3	0
164	116. Results of the NIMH FAST-MAS Phase IIa Proof of Mechanism Study of the Effects of the Selective μ -Opioid Antagonist JNJ-67953964 on fMRI Ventral Striatal Activity in Anhedonic Patients. <i>Biological Psychiatry</i> , 2019, 85, S48-S49.	1.3	0
165	5 Clinical Evaluation of the Abuse Potential of Buprenorphine/Samidorphan Combination. <i>CNS Spectrums</i> , 2019, 24, 176-176.	1.2	0
166	Cortical Gamma as a Marker of Kynurenine Pathway Engagement in Healthy Veterans Receiving L-4-Chloro-Kynurenine (AV-101). <i>Biological Psychiatry</i> , 2020, 87, S265.	1.3	0
167	The Evidence for Ketamine in Mood Disorders. <i>Psychiatric Annals</i> , 2020, 50, 44-45.	0.1	0